Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept Pharmaceuticals Inc.

www.interceptpharma.com

Latest From Intercept Pharmaceuticals Inc.

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint

The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of a trial in portal hypertension.

Liver & Hepatic Clinical Trials

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Financing Business Strategies

Intercept Retakes The Lead In NASH

A week after Gilead missed its primary endpoint in the first Phase III NASH trial, Intercept shows a statistically significant fibrosis benefit in Phase III with OCA. It plans to file for approval later this year.

Clinical Trials Liver & Hepatic

Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intercept Pharmaceuticals Inc.
  • Senior Management
  • Mark Pruzanski , MD, Pres. & CEO
    Sandip Kapadia, CFO
    David Shapiro, MD, CMO
  • Contact Info
  • Intercept Pharmaceuticals Inc.
    Phone: (646) 747-1000
    10 Hudson Yards
    37th Fl.
    New York, NY 10001
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register